SLU-PP-332 activates the same metabolic pathways your body turns on during endurance training, shifting muscle and fat tissue toward fat oxidation and mitochondrial production. If you train consistently but hit a plateau in endurance or body composition, this compound targets the cellular machinery that exercise itself depends on.
BEST FOR
Endurance support, fat loss, and metabolic optimization
METHOD
Subcutaneous injection
FREQUENCY
Daily or as directed by your provider, protocol length varies
SLU-PP-332 activates estrogen-related receptors (ERRs) in skeletal muscle, triggering the same gene expression changes that weeks of aerobic training produce. Preclinical studies show significant increases in running endurance in untrained subjects.
Unlike GLP-1 medications, SLU-PP-332 does not reduce hunger or slow gastric emptying. It shifts the body’s fuel preference toward fat oxidation, so you burn stored fat more efficiently throughout the day while your appetite stays normal.
ERR activation drives mitochondrial biogenesis in muscle tissue. More mitochondria means more cellular energy production, better metabolic flexibility, and improved recovery between training sessions.
SLU-PP-332 works through a distinct pathway from GLP-1 agonists, NNMT inhibitors, and growth hormone therapies. Our providers can evaluate whether it fits alongside your current protocol without overlap or interference.
SLU-PP-332 is a small-molecule compound developed at Saint Louis University that activates the estrogen-related receptor (ERR) family. Despite the name, ERRs do not bind estrogen. They regulate genes responsible for mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber composition.
When you train consistently, ERR activity increases in skeletal muscle and heart tissue. SLU-PP-332 activates these same receptors directly, producing metabolic adaptations that normally require sustained aerobic exercise. In preclinical research, subjects given SLU-PP-332 showed a measurable shift in body composition (including reduced fat mass and improved endurance) without changes to diet or activity level.
SLU-PP-332 is classified as an exercise mimetic, a compound that replicates some of the molecular effects of physical training. It is not a stimulant, not an appetite suppressant, and not a hormone. It works at the level of gene expression in muscle and fat tissue.
Our team orders baseline metabolic, hormone, and body composition labs to assess your current state. These results help determine whether SLU-PP-332 is the right fit and establish a clear starting point for tracking progress.
Your board-certified provider designs a personalized protocol based on your labs, goals, and any existing treatments. SLU-PP-332 is administered via subcutaneous injection, and your provider sets the dosing schedule that aligns with your physiology.
Once administered, SLU-PP-332 binds to ERR receptors in muscle and fat tissue. This triggers increased mitochondrial production, shifts fuel preference toward fat oxidation, and promotes the development of oxidative (slow-twitch) muscle fibers over weeks of consistent use.
We recheck labs and body composition at regular intervals. Your dedicated Health Coach tracks subjective feedback (energy, endurance, recovery) and our providers adjust dosing as the data comes in.
No. SLU-PP-332 is a small-molecule compound that gets grouped with peptides because peptide therapy providers carry it. Saint Louis University developed it as a selective activator of estrogen-related receptors (ERRs), which regulate energy metabolism and mitochondrial function.
Completely different mechanisms. Semaglutide reduces appetite and slows gastric emptying. SLU-PP-332 does not affect appetite at all. It increases how efficiently your body burns fat by activating the metabolic pathways that endurance exercise turns on. Some patients use both in combination under provider supervision.
No. Current evidence comes from preclinical (animal) studies, not completed human clinical trials. Our board-certified providers evaluate the available research and your individual health profile before recommending any compound, and they monitor your progress with lab work throughout your protocol.
Preclinical studies report no significant toxicity at effective doses. Anecdotal reports include mild elevations in heart rate and minor gastrointestinal discomfort, both transient. Our providers review your full health history before prescribing and monitor for changes throughout your protocol.
Most patients report improvements in endurance and energy within two to four weeks. Body composition changes typically show up around weeks four to eight.
